BlossomHill Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BLSM Nasdaq 2830 bhtherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer - Sep 1st, 2026 5:00 am
Insiders Are Betting Big on These 3 Healthcare Stocks - Aug 31st, 2026 11:20 am
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC - Aug 18th, 2026 5:00 am
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering - Aug 6th, 2026 6:07 pm